RAPT vs ABCL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Options & Structure while RAPT counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, RAPT trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ABCL at 27.6x Forward P/E and -1550.0% operating margin (-76.3% YoY). In options structure, RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RAPT | ABCL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $3.8B | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | -100.0% | -76.3% | Higher Growth | ABCL |
| Operating Margin (TTM) Profitability | 0.0% | -1550.0% | Higher Margin | RAPT |
| Net Profit Margin Profitability | 0.0% | -248.8% | Higher Margin | RAPT |
| Return on Equity (ROE) Capital Efficiency | -85.4% | -17.3% | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 100% ($1โ$58) | 68% ($3โ$15) | Stronger Trend | RAPT |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 2% Vol | 2.30ฮฒ ยท 87% Vol | Lower Realized Risk | RAPT |
| Unified Institutional Score Composite Signal | 52.4 / 100 (HOLD) | 63.3 / 100 (BUY) | Higher Composite | ABCL |